Cell-O-Matic (High Throughput Systematic Single-cell Genomics using Micro/Nano-Fluidic Chips for Extracting, Pre-analysis, Selecting and Preparing Sequence-ready DNA) consortium is made up of 13 partners-2 academic research groups, 9 SME's and 2 industries- from 8 different member states and funded by the seventh Framework FP-HEALTH.2011. This consortium will aim at developing methods that enable whole chromosome lengths of DNA to be contiguously mapped using nanofluidics. The Cell-0-Matic project will also synergize efforts to develop chip-based technologies that process DNA from individual cells, ready for Next-Generation high-throughput sequencing. Hélène Pendeville Ph.D., R&D Manager Associate noted: "Improving the quality and throughput of sequencing technologies to access genome information at a single-cell level will have a profound impact on systems biology, including cancer. Diagenode is proud to be part of this exciting 4-year programme".
Diagenode is a multinational life science company that develops and commercializes innovative instruments and reagents for epigenetic research. Major product lines include SX-8G IP-Star® Automation, Bioruptor® Sonication, epigenetic targeted ChIP-seq grade antibodies, kits for Chromatin Immunoprecipitation and DNA methylation studies. Founded in 2003 in Liège (Belgium), Diagenode has offices in Liège, Belgium and Denville, New Jersey.
R&D Manager Associate
March 13th 2012